Exosome Research Market Size, Share, Trends and Revenue | Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), System Biosciences, LLC (US), QIAGEN (Germany), Lonza (Switzerland)

Exosome Research Market in terms of revenue was estimated to be worth $169 million in 2023 and is poised to reach $356 million by 2028, growing at a CAGR of 16.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growing interest in exosome-based therapies, and the rising prevalence of chronic diseases like cancer has attracted substantial funding and investment from both public and private sources. This financial support is crucial for research and development efforts. However, regulatory uncertainty in exosome research is the factor restraining market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=224782498&utm_source=Openpr

The reagents & kits segment accounted for the largest share by product & service in the exosome research market in 2022.

By products & services, the exosome research market has been categorized in reagents & kits, instruments, and services. The kits and reagents segment is further categorized as antibodies, isolation, purification, quantitation kits & reagents, and other kits & reagents. The kits & reagents segment accounted for the largest share of the global exosome research market in 2022. The large share of this segment can primarily be attributed to increasing demand for diagnostic procedures in chronic diseases, and commercial applications of exosomes.

The biomarkers segment accounted for the largest share in the application segment in 2022.

Based on the application, the global exosome research market is segmented into tissue regeneration, biomarkers, vaccine development, and other applications. In 2022, the other applications segment is expected to grow at the highest growth rate in the forecast period. The growth of this segment is mainly attributed to the increased funding for the diagnostics and treatments of other diseases.

The academic & research institute segment accounted for the largest share of the end user segment in the exosome research market in 2022.

Based on end users, the exosome research market has been segmented into academic research institutes, pharmaceutical & biotechnology companies, and hospitals & clinical testing laboratories. In 2022, the academic & research institutes, segment accounted for the largest share of the exosome research market. One of the major factors driving the growth of this segment is that exosomes hold immense potential in diagnostics and therapeutics, including drug delivery and regenerative medicine. The enthusiasm surrounding these potential applications has fueled increased research efforts within academic and research institutions.

The North American region catered for the largest share of the exosome research market in 2022.

The exosome research market is segmented into North America, Europe, the Asia Pacific (APAC), Rest of World. The availability of funding, both public and private key companies, plays an important part in the development and commercialization of advanced technologies. Further, advanced healthcare infrastructure, robust research ecosystem, significant investments in biotechnology, supportive government policies, and a favorable regulatory environment collectively foster the development and commercialization of exosome-based solutions.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=224782498&utm_source=Openpr

Exosome Research Market Dynamics:

Drivers:

Rising cancer prevalence
Restraint:

Technical complexity of exosome isolation and technological limitations
Opportunities:

Increasing demand for personalized medicine
Challenge:

Limited understanding of cargo loading
Key Market Players of Exosome Research Industry:

Key players in the exosome research market include Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), System Biosciences, LLC (US), QIAGEN (Germany), Lonza (Switzerland), NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotech (Germany), Norgen Biotek Corp. (Canada), AMSBio (UK), Aethlon Medical, Inc. (US), Anjarium Biosciences AG (UK), Ciloa (France), InnovaPrep LLC (US), Creative Medical Technologies Holdings, Inc. (US), ILIAS Biologics, Inc. (South Korea), Unchained Labs (US), Rion, Inc. (US), Cell Guidance System, LLC (UK), INOVIQ (Australia), Danaher Corporation (US), Exopharm (Australia), Everzom (France), RoosterBio, Inc. (US), and Creative Biolabs (US).

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%
By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=224782498&utm_source=Openpr

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/exosome-research-product-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/exosome-research-product.asp

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

This release was published on openPR.